A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC.

被引：0
|
作者：
Ricciuti, Biagio [1 ]
Arbour, Kathryn C. [2 ]
Mahadevan, Navin R. [3 ]
Alessi, Joao V. [1 ]
Lindsay, James [1 ]
Umeton, Renato [1 ]
Sinha, Rileen [1 ]
Hoojghan, Amir [1 ]
Vokes, Natalie [1 ]
Recondo, Gonzalo [1 ]
Lamberti, Giuseppe [1 ]
Polio, Andrew [1 ]
Rizvi, Hira [2 ]
Leonardi, Giulia [1 ]
Plodkowski, Andrew J. [2 ]
Felt, Kristen [1 ]
Sharma, Bijaya [1 ]
Tolstorukov, Michael Y. [1 ]
Janne, Pasi A. [1 ]
Van Allen, Eliezer M. [1 ]
Sholl, Lynette M. [3 ]
Rodig, Scott J. [3 ]
Hellmann, Matthew D. [2 ]
Awad, Mark M. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
490
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC.
    Castellanos, Emily
    Snider, Jeremy
    Ali, Siraj Mahamed
    Backenroth, Daniel
    Albacker, Lee A.
    Murugesan, Karthikeyan
    Li, Gerald
    Frampton, Garrett M.
    Alexander, Brian Michael
    Carson, Kenneth Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] CLINICOPATHOLOGIC AND GENOMIC CORRELATES OF TUMOR MUTATIONAL BURDEN AND ITS IMPACT ON PD-(L)1 INHIBITION EFFICACY IN NON-SMALL CELL LUNG CANCER ACCORDING TO DIFFERENT PD-L1 EXPRESSION SUBGROUPS
    Ricciuti, Biagio
    Mahadevan, Navin
    Umeton, Renato
    Alessi, Joao
    Polio, Andrew
    Vokes, Natalie
    Leonardi, Giulia
    Aguilar, Elizabeth
    Recondo, Gonzalo
    Lamberti, Giuseppe
    Lawrence, Marissa
    Janne, Pasi
    Van Allen, Eliezer
    Sholl, Lynette
    Awad, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A147 - A149
  • [3] Role of PD-L1 and Tumor Mutational Burden in NSCLC Immunotherapy
    Peters, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S74 - S74
  • [4] FREQUENT HIGH TUMOR MUTATIONAL BURDEN (TMB) AND PD-L1 EXPRESSION IN PRIMARY CNS LYMPHOMA (PCNSL)
    Sumrall, Ashley
    Phuphanich, Surasak
    Spetzler, David
    Gatalica, Zoran
    Xiu, Joanne
    Provenzano, Aaron
    Brenner, Andrew J.
    Subramaniam, Deepa
    Pandey, Majari
    Heimberger, Amy
    Kesari, Santosh
    Korn, W. Michael
    Mittal, Sandeep
    NEURO-ONCOLOGY, 2018, 20 : 240 - 241
  • [5] Tumor Mutational Burden and PD-L1 Expression in Hematologic Malignancies
    Thomas, Sean D.
    Jeong, Ah-Reum
    Sakowski, Patrick J.
    Sokol, Ethan S.
    Kurzrock, Razelle
    Goodman, Aaron M.
    BLOOD, 2020, 136
  • [6] Biopsy and re-biopsy for PD-L1 expression in NSCLC. association between PD-L1 and checkpoint inhibitor efficacy through treatment in NSCLC. A pilot study
    Zarogoulidis, Paul
    Petridis, Dimitris
    Huang, Haidong
    Bai, Chong
    Hohenforst-Schmidt, Wolfgang
    Freitag, Lutz
    Baka, Sofia
    Drougas, Dimitris
    Vagionas, Anastasios
    Tsakiridis, Kosmas
    Turner, J. Francis
    Hatzibougias, Dimitris
    Boukovinas, Ioannis
    Zaric, Bojan
    Kovacevic, Tomi
    Ioannidis, Aris
    Courcoutsakis, Nikolaos
    Matthaios, Dimitris
    Sardeli, Chrisanthi
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (11) : 1483 - 1491
  • [7] Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.
    Seeber, Andreas
    Puccini, Alberto
    Xiu, Joanne
    Goldberg, Richard M.
    Grothey, Axel
    Shields, Anthony Frank
    Salem, Mohamed E.
    Battaglin, Francesca
    El-Deiry, Wafik S.
    Tokunaga, Ryuma
    Philip, Philip Agop
    Marshall, John
    Kocher, Florian
    Hall, Michael J.
    Korn, Wolfgang Michael
    Lenz, Heinz-Josef
    Spizzo, Gilbert
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] PD-L1 Very High Expression Associated with Clinical Outcome of Pembrolizumab Monotherapy of Advanced NSCLC with PD-L1 TPS of 50% or Greater
    Itani, H.
    Nigi, A.
    Iwamoto, K.
    Ito, Y.
    Tanigawa, M.
    Kondo, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S662 - S663
  • [9] Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis
    Li, Wenjie
    Zhao, Yanjun
    Zhang, Hongjun
    Zheng, Wenying
    Wang, Ruixuan
    Gu, Xing
    MEDICINE, 2023, 102 (40) : E34990
  • [10] Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.
    Arbour, Kathryn Cecilia
    Mezquita, Laura
    Niamh Long
    Rizvi, Hira
    Auclin, Edouard
    Ni, Ai
    Bernal, Gala Martinez
    Chaft, Jamie E.
    Ferrara, Roberto
    Lai, Wei-Chu Victoria
    Hendriks, Lizza
    Sabari, Joshua K.
    Caramella, Caroline
    Plodkowski, Andrew J.
    Halpenny, Darragh
    Planchard, David
    Riely, Gregory J.
    Besse, Benjamin
    Hellmann, Matthew David
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345